Associate Director, Research Core, VA VISN 5 Mental Illness Research, Education, and Clinical Center (MIRECC)
VA Annex, 735
Education and Training
- Mercer University College of Pharmacy (Magna cum laude), Pharm.D., 1993
- University of Maryland School of Pharmacy, Ph.D., 1999
Post Graduate Education and Training
- Post-doctoral fellowship, Maryland Psychiatric Research Center, University of Maryland School of Medicine, 2000
Dr. Kreyenbuhl’s primary research interest is the pharmacoepidemiology of serious mental illness (SMI). She has been the recipient of multiple grants from the NIH, VA, and private foundations in this area. She has contributed extensively to the development of evidence-based treatment guidelines for schizophrenia, serving as a co-investigator on the first update and principal investigator of grants funded by the NIMH and the VA to support the second update of the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. She has also served as the PI, Co-PI, or Co-I on local and federally funded efforts to study computer-technology based interventions for individuals with SMI, including the development and testing of a Smartphone application for enhancing adherence to antipsychotic medications. She has also received grant funding from VA HSR&D to develop an intervention to increase screening for the metabolic side effects of antipsychotic medications and to study how women Veterans with serious mental illnesses and their prescribers manage these side effects that are particularly distressing to women. She also has extensive experience using large administrative health services utilization databases for research. She has received support from the Stanley Medical Research Institute to use VA administrative data to identify novel non-psychotropic pharmacologic targets for the treatment of schizophrenia and bipolar disorder and to conduct comparative effectiveness analyses of antipsychotics in these populations. She has also used VA administrative data to investigate persistence of antipsychotic treatment in veterans with schizophrenia and adherence to hypoglycemic medications in veterans with and without schizophrenia. Her most current work involves using the 50-state Medicaid Analytic extracts and Medicare Part D administrative data to study expansion of advanced practice registered nurses’ prescriptive authority as one approach to addressing the significant psychiatrist-prescriber workforce shortage in the U.S.. Dr. Kreyenbuhl has authored or co-authored over 90 publications in peer-reviewed journals.
serious mental illness; health services research; pharmacoepidemiology
Weiser M, Davis J, Brown CH, Slade EP, Fang L, Medoff DR, Buchanan RW, Levi L, Davidson M, Kreyenbuhl J. Differences in antipsychotic treatment discontinuation among veterans with schizophrenia in the U.S. Department of Veterans Affairs. American Journal of Psychiatry. 2021 Jul 14:appiajp202020111657. doi: 10.1176/appi.ajp.2020.20111657. Epub ahead of print. PMID: 34256606.
Kreyenbuhl J, Dixon LB, Brown CH, Medoff DR, Klingaman EA, Fang L, Tapscott S, Walsh M. A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications. Community Mental Health Journal 2016 Apr 9. [Epub ahead of print] PubMed PMID: 27061185.
Kreyenbuhl J, Medoff DR, McEvoy JP, Smith TE, Hackman A, Nossel IR, Dixon LB, Essock SM, Buchanan RW. The RAISE Connection Program: Psychopharmacological Treatment of People with a First Episode of Schizophrenia. Psychiatric Services; 2016 Jul 1:appips201500438. [Epub ahead of print] PubMed PMID: 27364816.
Kreyenbuhl J, Record EJ, Palmer-Bacon J. A Review of Behavioral Tailoring Strategies for Improving Medication Adherence in Serious Mental Illness. Dialogues in Clinical Neuroscience 2016 Jun;18(2):191-201.
Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009. Schizophr Bull 2010 Jan; 36(1):94-103.
Kessler RC, Bauer MS, Bishop TM, Demler OV, Dobscha SK, Gildea SM, Goulet JL, Karras E, Kreyenbuhl J, Landes SJ, Liu H, Luedtke AR, Mair P, McAuliffe WHB, Nock M, Petukhova M, Pigeon WR, Sampson NA, Smoller JW, Weinstock LM and Bossarte RM. Using administrative data to predict suicide after psychiatric hospitalization in the Veterans Health Administration system. Front. Psychiatry 2020; 11:390. doi: 10.3389/fpsyt.2020.00390.
Kreyenbuhl J, Lucksted A, Despeaux K, Sykes VM. Understanding Women Veterans’ Experiences with and Management of Weight Gain from Medications for Serious Mental Illness: A Qualitative Study. Psychiatric Rehabilitation Journal 2019 Sept;42(3):238-245.
Travaglini LE, Kreyenbuhl J, Graydon M, Brown CH, Goldberg R, Himelhoch S, Fang LJ, Slade E. Access to sofosbuvir treatment for hepatitis C virus among veterans with serious mental illness. Psychiatric Services 2020 Feb 1;71(2):192-195. doi: 10.1176/appi.ps.201900227. Epub 2019 Oct 16. PMID: 31615365.
Reich CM, Hack SM, Klingaman EA, Brown CH, Fang LJ, Dixon LB, Jahn DR, Kreyenbuhl JA. Consumer Satisfaction with Antipsychotic Medication Monitoring Appointments: The Role of Consumer-Prescriber Communication Patterns. Int J Psychiatry Clin Pract. 2018 Jun; 22(2):89-94. doi: 10.1080/13651501.2017.1375530.
Ali MK, Hack SM, Brown CH, Medoff D, Fang L, Klingaman E, Park SG, Dixon LB, Kreyenbuhl JA. Racial Differences in Mental Health Recovery among Veterans with Serious Mental Illness. J Racial Ethn Health Disparities. 2018 Apr;5(2): 235-242.doi: 10.1007/s40615-017-0363-z.
Himelhoch S, Kreyenbuhl J, Palmer-Bacon J, Chu M, Medoff D, Potts W. Pilot Feasibility Study of Heart2HAART: A Smartphone Application to Assist with Adherence among Substance Users Living with HIV. AIDS Care 2017 Jul; 29(7):898-904.
Saeedi O, Ashraf H, Slade EP, Medoff DR, Li L, Friedman DS, Kreyenbuhl J. Trends in Prevalence of Diagnosed Ocular Disease and Utilization of Eye Care Services in American Veterans. Am J Ophthalmology 2017 Jan; 173:70-75.
Hack SM, Medoff DR, Brown CH, Fang L, Dixon LB, Klingaman EA, Park SG, Kreyenbuhl JA. Predictors of Patient Communication in Psychiatric Medication Encounters Among Veterans With Serious Mental Illnesses. Psychiatr Rehabil J. 2016 Jun; 39(2):183-6.
Record EJ, Medoff D, Dixon L, Klingaman E, Park S, Hack S, Brown C, Fang LJ, Kreyenbuhl J. Access to and use of the internet among veterans with serious mental illness. Community Mental Health Journal 2016; 52(2), 136-141.
Charlotte M, Schwartz E, Slade E, Medoff D, Li L, Dixon L, Kilbourne AM, Kreyenbuhl J. Gender differences in mood stabilizer medications prescribed to veterans with serious mental illness. Journal of Affective Disorders2015; 188: 112-117.
Schwartz E, Charlotte M, Slade E, Medoff D, Li L, Dixon L, Kilbourne A, Kreyenbuhl J. Gender Differences in Antipsychotics Prescribed to Veterans with Serious Mental Illness. General Hospital Psychiatry 2015; 37(4):347-51.
Klingaman EA, Medoff DR, Park SG, Brown CH, Fang L, Dixon LB, Hack S, Tapscott S, Walsh MB, Kreyenbuhl JA. Consumer satisfaction with psychiatric services: The role of shared decision-making and the therapeutic relationship. Psychiatric Rehabilitation Journal 2015; 38(3):242-8.
Essock SM, Nossel IR, McNamara K, Bennett ME, Buchanan RW, Kreyenbuhl JA, Mendon SJ, Goldman HH, Dixon LB. Practical Monitoring of Treatment Fidelity: Examples From a Team-Based Intervention for People With Early Psychosis. Psychiatr Services 2015 Jul;66(7):674-6.
Park SG, Derman M, Dixon LB, Brown CH, Klingaman EA, Fang LJ, Medoff DR, Kreyenbuhl J. Factors Associated With Shared Decision-Making Preferences Among Veterans With Serious Mental Illness. Psychiatric Services 2014; Dec 1;65(12):1409-13.
Long JA, Wang A, Medvedeva EL, Eisen SV, Gordon A, Kreyenbuhl J, Marcus SC. Glucose Control and Medication Adherence Among Veterans With Diabetes and Serious Mental Illness: Does Collocation of Primary Care and Mental Health Care Matter? Diabetes Care 2014 Aug; 37:1–7.
Aakre JM, Medoff DR, Dixon LB, Kreyenbuhl J. Beliefs about antipsychotic versus hypoglycemic medications among individuals with serious mental illness and type 2 diabetes. Patient Prefer Adherence 2012; 6:389-94.
Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. . Schizophrenia Research 2011; 131(1-3):127-32.
Kreyenbuhl J, Leith J, Medoff DR, Fang L, Dickerson FB, Brown C, Goldberg RW, Potts W, Dixon LB. A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. Psychiatry Research 2011; 188: 109-114.
Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for Type 2 diabetes differ between individuals with versus without schizophrenia? Schizophrenia Bulletin 2010; 36(2): 428-435.
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):71-93.
Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements. Schizophr Bull 2010 Jan; 36(1):48-70.
Kreyenbuhl J, Nossel IR, Dixon LB. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: A review of the literature. Schizophrenia Bulletin 2009; 35 (4):696-703.
Kreyenbuhl J, Medoff DR, Seliger SL, Dixon LB. Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes. Schizophrenia Research 2008; 101: 256-265.
Kreyenbuhl J, Marcus SC, West JC, Wilk J, Olfson M. Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services 2007; 58(7): 983-990.
Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Antipsychotic polypharmacy in the VA Health System: Patient characteristics and treatment patterns. Psychiatric Services 2007; 58(4): 489-495.
Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang L, Wohlheiter K, Mittal LP, Dixon LB. Extent and management of cardiovascular risk factors in patients with Type 2 diabetes and serious mental illness. Journal of Nervous and Mental Disease 2006; 194 (6): 404-410.
Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophrenia Research 2006 May; 84(1):90-99.
Lehman AF, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden L, Kreyenbuhl J. Evidence-based treatment for schizophrenia. Psychiatr Clin North Am 2003; 26(4): 939-54.